The development of AXA-042 is based on vaccine adjuvant research from the laboratory of Professor David Jackson at the Peter Doherty Institute for Infection and Immunity at the University of Melbourne. …
Australian company Axelia Oncology announces supply agreement for PBS-listed cancer medicine
February 17, 2025 Latest NewsBioPharmaAustralian Biotech
Latest Video
New Stories
-
Syntara’s topical anti-fibrotic drug leads to significant normalisation of skin in established scars
February 18, 2025 - - Australian Biotech -
Trump suspends law that changed the industry's approach to public affairs
February 18, 2025 - - Latest News -
Pharmx Technologies partners with Toniq to expand pharmacy solutions in New Zealand
February 18, 2025 - - Latest News -
Pfizer teams up with Heart of Australia to expand access to GP education
February 18, 2025 - - Latest News -
HMRI partners with Novartis to supercharge heart health impact
February 17, 2025 - - Latest News -
PYC Therapeutics to raise up to $146 million to support late-stage trials
February 17, 2025 - - Australian Biotech -
Australia isn’t ready for the next cardiac epidemic, warns landmark heart valve disease report
February 17, 2025 - - Latest News